DIMERx INC. News Releases

DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence

Tue, 12 May 2026 09:00:00 -0400

Key Regulatory Benchmark Met, Differentiating DMX-101 from Traditional Opioid AnalgesicsLate-Breaking Results to be Presented at CPDD 2026 Annual MeetingSan Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without...

Jeffrey W. Sherman, MD, Joins DIMERx Board to Advance Next-Generation, Non-Addictive Pain Therapies

Tue, 03 Mar 2026 09:00:00 -0500

San Francisco, California--(Newsfile Corp. - March 3, 2026) - DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. The Company announced the appointment of Jeffrey W. Sherman, MD, FACP, to its Board of Directors. Dr....